Senior researcher Wietske Kievit (department for Health Evidence) and PhD candidate Floor Berden (Gastroenterology and Hepatology) have illustrated this paradox in recent papers published in PlosOne and NTvG.Paradox
Pharmaceutical companies are under increasing scrutiny because of their strategy for gaining market access and reimbursement authorisation for novel drugs. The tool most often used is that of a randomised controlled trial (RCT) in a highly selected population that has a high chance of responding on the treatment but a low chance of developing side effects. This population differs to a large extent from real-life patients, who have diverging characteristics that can influence effectiveness and safety; these include co-morbidity, age and disease severity. This leads to the paradox that medicines are being used in daily practice for situations and patients which are not investigated in the original trials.
Senior research Wietske Kievit (department for Health Evidence) and PhD candidate Floor Berden (Gastroenterology and Hepatology) have illustrated this paradox in a recent paper published in PlosOne. They researched the situation with protease inhibitors telaprevir and boceprevir for hepatitis C patients. Nearly half of real world hepatitis C patients would have been excluded from registration trials, and these patients developed more serious adverse events than eligible patients .
In a publication in the journal ‘Nederlands Tijdschrift voor Geneeskunde (NTvG)’Kievit and Berden discuss research designs that can complement findings from RCTs, such as pragmatic trials, enriched trials, adaptive pathways, early access programs and patient registries. The aim is to stimulate debate among different stakeholders so that they answer the right question at the right time using a suitable research methodology.
PlosOne: Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study
NTvG: Nieuwe geneesmiddelen sneller beschikbaar voor juiste patiënt
Te streng deurbeleid registratiestudies
Related news items
RIMLS award ceremony proudly presenting the winners16 January 2020
Several RIMLS researchers received an award and bonus during the New Year's drinks. See all photo's and the ENABLE aftermovie.read more
The PRIDE Study Evaluation of online methods of data collection16 January 2020
In Paediatric and Perinatal Epidemiology RIHS researchers Marleen van Gelder and Nel Roeleveld described the recruitment methods and online data collection within the PRIDE Study, the largest Dutch birth cohort study.read more
Laparoscopy reduces the number of adhesions but it is still too high14 January 2020
Adhesions after abdominal surgery cause too many re-admissions. Although keyhole surgery reduces the number of adhesions and the complications associated with them, the total disease burden remains high, as reported in The Lancet by RIHS researcher Richard ten Broek and colleagues.read more
Rubicon Grant for Marieke Klein14 January 2020
DCMN researcher Marieke Klein, theme Neurodevelopmental disorders, received a Rubicon Grant from the Dutch Organisation for Scientific Research (NWO). The Rubicon program gives young, highly promising researchers the opportunity to gain international research experience.read more
Radboud Talks 2020 scientific pitch competition14 January 2020
The next edition of Radboud Talks will take place in the spring. During this academic pitch competition, young researchers will be given the opportunity to share their stories with a large audience. In a three-minute presentation, you will talk about your research in a fun and accessible manner.read more